Press release
Neuroblastoma Market Expansion Continues, with Forecast Valuation of $3.91 Billion by 2029
Neuroblastoma
Neuroblastoma Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The neuroblastoma market has experienced robust expansion lately, projected to move from $2.97 billion in 2024 to $3.14 billion just one year later, reflecting a compound annual growth rate of 5.7%; this upward trajectory during the past period is traceable to several factors, including a rising prevalence of neuroblastoma, greater investment in developing novel treatments for pediatric neuroblastoma, a climbing rate of childhood cancer occurrences, and augmented financial backing and assistance furnished by governmental bodies.
Neuroblastoma Market Size Forecast: What's the Projected Valuation by 2029?
Forecasting robust expansion for the neuroblastoma sector, the market valuation is projected to reach $3.91 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 5.6% across the upcoming period. This upward trajectory is underpinned by several key factors, notably augmented financial backing from governmental bodies, the rising occurrence of the ailment, a greater emphasis being placed on identifying the condition sooner, the growing presence of genetic alterations, and continuous progression in both the comprehension of the disease and related research breakthroughs. Furthermore, prevailing shifts influencing this market encompass the creation of therapeutics aimed at precise molecular routes, technological leaps in imaging methods that avoid invasive procedures, progress in gene modification techniques, a heightened dedication to tailoring therapies to individual patients, and the advent of novel radiolabeled agents.
View the full report here:
https://www.thebusinessresearchcompany.com/report/neuroblastoma--global-market-report
What Are the Drivers Transforming the Neuroblastoma Market?
Anticipated expansion in the occurrence of pediatric malignancies is set to fuel the progression of the neuroblastoma market in the coming period. Pediatric cancer encompasses various malignancies predominantly impacting younger individuals and adolescents, often involving sites like the brain, blood systems, and skeletal structures, thus demanding highly specialized therapeutic modalities. This escalating frequency in childhood cancer diagnoses is linked to several contributors, which include enhancements in detection methodologies, heightened public and clinical cognizance, exposure to environmental agents, inherent genetic susceptibilities, and breakthroughs in medical science. Neuroblastoma therapies offer focused treatment strategies for these childhood cancers, facilitating prompt and successful management that concurrently diminishes the likelihood of relapse and enhances recovery prospects for juvenile recipients of care. To illustrate this trend, data from the American Cancer Society, a professional US organization, indicated that for the year 2024, an estimated 9,620 children under fifteen years old within the United States are forecast to receive a cancer diagnosis, marking an increase when compared to the 5,290 cases reported in 2023. Consequently, the heightened rate of childhood cancer incidence functions as a catalyst for the expansion of the neuroblastoma market.
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20901&type=smp
What Long-Term Trends Will Define the Future of the Neuroblastoma Market?
Leading firms within the neuroblastoma arena are prioritizing the creation of sophisticated treatment modalities, exemplified by the design of humanized anti-GD2 monoclonal antibodies, aiming for superior efficacy and enhanced patient safety when confronting malignant cells. This particular type of monoclonal antibody, being partially human in composition, is specifically modified to bind to the GD2 antigen present on cancer cells, thereby mitigating the risk of immune system rejection. A concrete illustration of this development came in August of 2023 when Renaissance Pharma Ltd., a pharmaceutical entity currently in the clinical development phase and headquartered in the United Kingdom, finalized an agreement to acquire the rights to Hu14.18K322A (referred to as Hu14.18) from St. Jude Children's Research Hospital. This antibody has been specifically formulated for application in cases of newly diagnosed, high-risk neuroblastoma, which represents an uncommon and highly virulent form of pediatric malignancy. The contractual arrangement bestows upon Renaissance the sole authority to spearhead the research, production, and market introduction of Hu14.18 throughout crucial international territories, encompassing the United States, Canada, the entirety of Europe, China, Japan, and Turkey.
Which Segments in the Neuroblastoma Market Offer the Most Profit Potential?
The neuroblastomamarket covered in this report is segmented -
1) By Product Types: Tablets; Vaccines; Other Product Types
2) By Treatment Type: Chemotherapy; Immunotherapy; Other Treatment Types
3) By Distribution Channel: Online; Offline
4) By End-User: Hospitals; Clinics
Subsegments:
1) By Tablets: Oral Chemotherapy Tablets; Targeted Therapy Tablets
2) By Vaccines: Immunotherapy Vaccines; Therapeutic Vaccines
3) By Other Product Types: Injectable Drugs; Monoclonal Antibodies; Cell Therapy Products
Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=20901&type=smp
Which Firms Dominate the Neuroblastoma Market by Market Share and Revenue in 2025?
Major companies operating in the neuroblastoma market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Sartorius AG, Recordati S.p.A, United Therapeutics Corporation, BeiGene Ltd., MacroGenics Inc., Y-mAbs Therapeutics Inc., RedHill Biopharma Ltd., Clarity Pharmaceuticals Ltd., EUSA Pharma (UK) Ltd., US WorldMeds LLC, Healio Inc., Ascentage Pharma, Laboratorio Elea Phoenix S.A, Curis Inc., PersonGen BioTherapeutics (Suzhou) Co. Ltd., Essential Pharma S.A, Cellectar Biosciences Inc., Provectus Biopharmaceuticals Inc.
Which Regions Offer the Highest Growth Potential in the Neuroblastoma Market?
North America was the largest region in the neuroblastoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neuroblastoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20901
This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.
Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Neuroblastoma Market Expansion Continues, with Forecast Valuation of $3.91 Billion by 2029 here
News-ID: 4279331 • Views: …
More Releases from The Business Research Company
Competitive Landscape: Key Market Leaders and Emerging Participants in the Ultra …
The demand for ultra pure water is on a sharp rise, driven by its critical role across multiple high-tech and industrial sectors. As industries continue to advance, ensuring the availability of water free from contaminants becomes increasingly vital. Let us explore the current market outlook, key players, emerging trends, and segment details shaping the ultra pure water market's future.
Expected Market Size and Growth Outlook for Ultra Pure Water
The ultra…
Future Perspectives: Key Trends Shaping the Styrene-Petrochemicals Market Up to …
The styrene-petrochemicals sector is positioned for steady expansion in the coming years, driven by diverse industrial demands and evolving market trends. Understanding the current landscape, key players, and emerging innovations sheds light on the future trajectory of this important chemical market.
Expected Growth and Market Size of the Styrene-Petrochemicals Industry
The styrene-petrochemicals market is projected to reach a value of $82.11 billion by 2029, growing at a compound annual growth rate…
Segmentation, Main Trends, and Competitive Overview of the Silicone Market
The silicone market is poised for significant expansion over the coming years, driven by various technological and environmental factors. This sector is rapidly evolving to meet the rising demand across multiple industries, fueled by innovations and sustainability trends. Let's explore the market's size, key players, growth drivers, emerging trends, and segmentation to understand the future outlook better.
Projected Expansion of the Silicone Market by 2029
The silicone market is expected to…
Competitive Landscape: Leading Companies and New Entrants in the Printing Inks M …
The printing inks market is on a steady upward path, driven by evolving technological innovations and growing demands from various industries. As the need for sustainable and efficient printing solutions increases, this sector is poised for significant expansion in the coming years. Below is a detailed overview of the market size, key players, trends, and segmentation shaping the future of printing inks.
Expected Market Size and Growth Prospects of the Printing…
More Releases for Neuroblastoma
Pediatric Relapsed & Refractory Neuroblastoma Market Trades 2034
Market Overview
The Pediatric Relapsed and Refractory Neuroblastoma Market is expanding as unmet needs remain high for children who fail first-line therapy or experience disease recurrence. Neuroblastoma, a rare pediatric cancer originating in nerve tissues, poses significant treatment challenges when it becomes resistant or relapses after conventional chemotherapy, surgery, and radiation. As a result, demand for novel immunotherapies, targeted biologics, CAR-T therapies, and precision medicine is accelerating globally. Improved survival outcomes,…
Neuroblastoma Market Massive Growth opportunity Ahead
Neuroblastoma market Size, Status, and Forecast for the 2025-2034. In-depth research has been compiled to provide the most up-to-date information on key aspects of the worldwide market. This research report covers major aspects of the Neuroblastoma Market including drivers, restraints, historical and current trends, regulatory scenarios, and technological advancements. It provides the industry overview with growth analysis and historical & futuristic cost, revenue, demand and supply data (as applicable). The…
Pediatric Neuroblastoma Treatment Market - Redefining Possibilities: Advancement …
Newark, New Castle, USA: The "Pediatric Neuroblastoma Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Pediatric Neuroblastoma Treatment Market: https://www.growthplusreports.com/report/pediatric-neuroblastoma-treatment-market/7681
This latest report researches the industry structure,…
Neuroblastoma Treatment Market Projected to Garner Significant Revenues by 2024
Neuroblastoma is the most common type of cancer in infants. The cancer is caused as a result of embryonal malignancy of sympathetic nervous system which arises from the neuroblasts. The cancer develops in the nerve tissues of adrenal, chest or spinal cord. Neuroblastoma is listed as a “rare disease” in the U.S. by the National Institute of Health (NIH), and Orphanet in Europe. The cancer is most prevalent in infants…
Neuroblastoma Drugs Market Size, Share, Development by 2024
New report published by Global Info Research which offers insights on the Global Neuroblastoma Drugs market.
Neuroblastoma (NB) is a type of cancer that forms in certain types of nerve tissue. It most frequently starts from one of the adrenal glands, but can also develop in the neck, chest, abdomen, or spine. Symptoms may include bone pain, a lump in the abdomen, neck, or chest, or a painless bluish lump under…
Global Neuroblastoma Treatment Market: Latest Trends and Insights 2023
Neuroblastoma is the most common type of cancer in infants. The cancer is caused as a result of embryonal malignancy of sympathetic nervous system which arises from the neuroblasts. The cancer develops in the nerve tissues of adrenal, chest or spinal cord. Neuroblastoma is listed as a “rare disease” in the U.S. by the National Institute of Health (NIH), and Orphanet in Europe. The cancer is most prevalent in infants…
